Management of the Treatment-Experienced Patient Infected with Hepatitis C Virus Genotype 1: Options and Considerations

Clinics in Liver Disease

Volumn 15, Issue 3, 2011, Pages 573-583

  Khalid, Omer ^a   Bacon, Bruce R ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Boceprevir; Consensus interferon; Difficult to treat patients; Genotype 1; Hepatitis C; IL 28B polymorphism; NS3 protease inhibitor; Telaprevir

Indexed keywords

BOCEPREVIR; NONSTRUCTURAL PROTEIN 3; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR;

CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; REVIEW; TREATMENT DURATION; TREATMENT FAILURE; VIRAL GENETICS; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; INTERLEUKINS; RIBAVIRIN; VIRAL NONSTRUCTURAL PROTEINS;

EID: 80051939682     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2011.05.001     Document Type: Review

References (33)

1. Alter M.J., Kruszon-Moran D., Nainan O.V., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999, 341(8):556-562.
2. Hepatitis C-global prevalence. Wkly Epidemiol Rec 1999, 49:425-427. WHO.
3. Lauer M.G., Walker D.B. Hepatitis C virus infection. N Engl J Med 2001, 345(1):41-52.
4. Leevy C.B. Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin. Dig Dis Sci 2008, 53:1961-1966.
5. Saracco G., Rizzetto M. Predictors of response to interferon therapy. Dig Dis Sci 1996, 41:115S-120S.
6. Moreno L., Quereda C., Moreno A., et al. Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV infected patients. AIDS 2004, 18:67-73.
7. Kasahara A., Hayashi N., Mochizuki K., et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998, 27:1394-1402.
8. Yoshida H., Shiratori Y., Moriyama M., et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and non-cirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999, 131:174-181.
9. Bacon B.R., Shiffman M.L., Mendes F., et al. Retreating chronic hepatitis C with daily interferon Alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: direct results. Hepatology 2009, 49:1838-1846.
10. Fried M.W., Hadziyannis S.J., Shiffman M.L., et al. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011, [Epub ahead of print].
11. Hoofnagle J.H. A step forward in therapy for hepatitis C. N Engl J Med 2009, 360(18):1899-1901.
12. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
13. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001, 358:958-965.
14. Hadziyannis S.J., Sette H., Morgan T.R., et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin combination therapy in chronic hepatitis C: a randomized study of the effect of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-355.
15. Conjeevaram H.S., Fried M.W., Jeffers L.J., et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006, 131:470-477.
16. Rodriguez-Torres M., Jeffers L.J., Sheikh M.Y., et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med 2009, 360:257-267.
17. Ghany G.M., Strader B.D., Thomas L.D., et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49(4):1335-1374.
18. Poynard T., Colombo M., Bruix J., et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009, 136:1618-1628.
19. Jensen D.M., Marcellin P., Freilich B., et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alfa2b. Ann Intern Med 2009, 150:528-540.
20. Kaiser S., Lutze B., Sauter B., et al. Retreatment of HCV genotype 1 relapse patients to peginterferon/ribavirin therapy with an extended treatment regimen of 72 weeks with consensus interferon/ribavirin versus peginterferon alpha/ribavirin. Hepatology 2007, 46(4 SUPPL 1):819.
21. Thompson A.J., Muir A.J., Sulkowski M.S., et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in the genotype 1 hepatitis C virus. Gastroenterology 2010, 139:120-129.
22. Poordad F., Bronowicki J.P., Gordon S.C., et al. IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with boceprevir (BOC) combination therapy. J Hepatol 2011, 54:S6.
23. Kwo P.Y., Lawitz E.J., McCone J., et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376(9742):705-716.
24. Berman K., Kwo P.Y. Boceprevir, an NS3 protease inhibitor of HCV. Clin Liver Dis 2009, 13(3):429-439.
25. McHutchison J.G., Everson G.T., Gordon S.C., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009, 360:1827-1838.
26. Hézode C., Forestier N., Dusheiko G., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009, 360:1839-1850.
27. Sherman KE, Flamm SL, Afdhal NH. Telaprevir in combination with peginterferon alfa2a and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achieved an extended rapid viral response: final results of phase 3 ILLUMINATE study. 61st AASLD; Boston (MA), October 29 to November 2010. Hepatology 2010;52:106A.
28. Jacobson IM, McHutchison GJ, Dusheiko MG. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of phase 3 ADVANCE study. 61st AASLD; Boston (MA), October 29 to November 2010. Hepatology 2010;52:427A.
29. McHutchison J.G., Manns M.P., Muir A.J., et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010, 362:1292-1303.
30. Poordad F., McCone J., Bacon B.R., et al. Boceprevir with peginterferon/ribavirin for untreated chronic hepatitis C. N Engl J Med 2011, 54:1195-1206.
31. Bacon B.R., Gordon S.C., Lawitz E., et al. Boceprevir for treatment of chronic hepatitis C genotype 1 nonresponders. N Engl J Med 2011, 54:1207-1217.
32. Foster GW, Zeuzem S, Andreone P, et al. Telaprevir-based therapy in genotype 1 hepatitis C virus-infected patients with prior null response, partial response or relapse to peginterferon/ribavirin: REALIZE Trial Final Results. Oral presentation, Asia Pacific Association for the Study of Liver, Bangkok (Thailand), February 18, 2011.
33. Poordad F. Big changes are coming in hepatitis C. Curr Gastroenterol Rep 2011, 13(1):72-77.